Advertisement

Visfatin—a proinflammatory adipokine—in gallstone disease

      Abstract

      Background

      Visfatin is increasingly associated with several obesity-related diseases. The study is to evaluate if aberrant expression of circulating visfatin occurs in gallstone disease.

      Methods

      An enzyme-linked immunosorbent assay was used to examine serum visfatin levels in 79 patients with cholesterol gallstones, 71 with pigment gallstones, and 223 healthy controls. The chemical composition of extracted gallstones was determined by Fourier transform infrared spectroscopy.

      Results

      Serum visfatin levels were markedly elevated in the cholesterol and pigment gallstones in comparison with healthy controls. Furthermore, increased visfatin levels were associated with formation of the cholesterol and pigment gallstones. Intriguingly, a significant positive correlation between serum visfation levels and white cell count was noted in the cholesterol gallstones and controls. Moreover, the positive correlation in the cholesterol gallstones was more significant in the body mass index ≥25 subgroup than in the body mass index <25 subgroup.

      Conclusions

      Gallstone disease is associated with altered circulating visfatin. The proinflammatory effect of circulating visfatin in gallstone disease deserves further investigation.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Everhart J.E.
        • Khare M.
        • Hill M.
        • et al.
        Prevalence and ethnic differences in gallbladder disease in the United States.
        Gastroenterology. 1999; 117: 632-639
        • Halldestam I.
        • Enell E.L.
        • Kullman E.
        • et al.
        Development of symptoms and complications in individuals with asymptomatic gallstones.
        Br J Surg. 2004; 91: 734-738
        • Acalovschi M.
        Cholesterol gallstones: from epidemiology to prevention.
        Postgrad Med J. 2001; 77: 221-229
        • Shaffer E.A.
        Gallstone disease: epidemiology of gallbladder stone disease.
        Best pract res clin Gastroenterol. 2006; 20: 981-996
        • Donovan J.M.
        Physical and metabolic factors in gallstone pathogenesis.
        Gastroenterol Clin North Am. 1999; 28: 75-97
        • Hsing A.W.
        • Sakoda L.C.
        • Chua Jr, S.
        Obesity, metabolic syndrome, and prostate cancer.
        Am J Clin Nutr. 2007; 86: s843-s857
        • Yeh M.M.
        • Brunt E.M.
        Pathology of nonalcoholic fatty liver disease.
        Am J Clin Pathol. 2007; 128: 837-847
        • Calle E.E.
        • Kaaks R.
        Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.
        Nat Rev Cancer. 2004; 4: 579-591
        • Tilg H.
        • Moschen A.R.
        Adipocytokines. Mediators linking adipose tissue, inflammation and immunity.
        Nat Rev Immunol. 2006; 6: 772-783
        • Samal B.
        • Sun Y.
        • Stearns G.
        • et al.
        Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.
        Mol Cell Biol. 1994; 14: 1431-1437
        • Fukuhara A.
        • Matsuda M.
        • Nishizawa M.
        • et al.
        Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
        Science. 2005; 307: 426-430
        • McGlothlin J.R.
        • Gao L.
        • Lavoie T.
        • et al.
        Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.
        Biochem Genet. 2005; 43: 127-141
        • Wang S.N.
        • Yeh Y.T.
        • Yu M.L.
        • et al.
        Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease.
        Eur J Clin Invest. 2006; 36: 176-180
        • Wang S.N.
        • Yeh Y.T.
        • Yu M.L.
        • et al.
        Serum adiponectin levels in cholesterol and pigment cholelithiasis.
        Br J Surg. 2006; 93: 981-986
        • Mantsch H.H.
        • Chapman D.
        Infrared Spectroscopy of Biomolecules.
        John Wiley, New York1996
        • Kleiner O.
        • Ramesh J.
        • Huleihel M.
        • et al.
        A comparative study of gallstones from children and adults using FTIR spectroscopy and fluorescence microscopy.
        BMC Gastroenterol. 2002; 2: 3-16
        • Trotman B.W.
        • Soloway R.D.
        Pigment gallstone disease: summary of the National Institutes of Health -international workshop.
        J Hepatol. 1982; 2: 879-884
        • Cetta F.
        • Lombardo F.
        • Giubbolini M.
        • et al.
        Classification of gallstones and epidemiologic studies.
        Digest Dis Sci. 1995; 40: 2189-2191
        • Choi K.M.
        • Lee J.S.
        • Kim E.J.
        • et al.
        Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
        Eur J Endocrinol. 2008; 158: 203-207
        • Tilg H.
        • Moschen A.R.
        Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.
        Clin Sci (Lond). 2008; 114: 275-288
        • Filippattos T.D.
        • Derdemezis C.S.
        • Kiortsis D.N.
        • et al.
        Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.
        J Endocrinol Invest. 2007; 30: 323-326
        • Arner P.
        Visfatin—a true or false trail to type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2006; 91: 28-30
        • Haider D.G.
        • Schindler K.
        • Schaller G.
        • et al.
        Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
        J Clin Endocrinol Metab. 2006; 91: 1578-1581
        • Jin H.
        • Jiang B.
        • Tang J.
        • et al.
        Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
        Diabetes Res Clin Pract. 2008; 79: 412-418
        • Ye S.Q.
        • Somon B.A.
        • Maloney J.P.
        • et al.
        Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury.
        Am J Respir Crit Care Med. 2005; 171: 361-370
        • Bajwa E.K.
        • Yu C.L.
        • Gong M.N.
        • et al.
        Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.
        Crit Care Med. 2007; 35: 1290-1295
        • Jia S.H.
        • Li Y.
        • Parodo J.
        • et al.
        Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.
        J Clin Invest. 2004; 113: 1318-1327

      Linked Article

      • Visfatin and gallstone disease
        The American Journal of SurgeryVol. 203Issue 3
        • Preview
          Visfatin is a recently described adipose tissue–derived protein, which has insulin-mimetic actions. Adipocyte visfatin expression and plasma concentrations increase in some, but not all, forms of obesity, both in animals and humans. Visfatin exerts its insulin-mimetic action by binding to the insulin receptor, and there is evidence that it may contribute to the development of the metabolic syndrome.1
        • Full-Text
        • PDF